Figure 2.

Genetic deletion or pharmacological inhibition of RANK reduces the incidence of Brca1 deletion-driven mammary tumorigenesis. (A) Onset of palpable mammary tumors in WapCre^C;Brca1;p53 and WapCre^C;Rank;Brca1;p53 mice. Data are shown as percentage of tumor-free mice. (B) Representative histological sections of mammary tumors isolated from WapCre^C;Brca1;p53 and WapCre^C;Rank;Brca1;p53 mice showing different histological grades (H&E) and altered, grade-dependent KRT5/CK5 immunostainings. Scale bar, 100 μm. (C) Schematic of the regimen used to treat MMTV-CreBrca1^{flox11/flox11} mice with control Mu-Fc or RANK-Fc to block RANKL/RANK in vivo. (D) Numbers and percentages of MMTV-Cre Brca1^{flox11/flox11} mice with pre-neoplastic lesions that received subcutaneous (sc) injection of Mu-Fc or RANK-Fc for 6 or 12 months (3 times/week) and were sacrificed for analysis at 9 and 15 month of age. (E) Representative H&E-stained sections of mammary tissue of MMTV-CreBrca1^flox11 mice that received Mu-Fc or RANK-Fc and were sacrificed at 15 month of age. Magnification, 400×.